Drugs / PLX-61639
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07284186 | Dec 2025 → Dec 2029 expected | esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastric squamous cell carcinoma +3 | Plexium, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Plexium, Inc. | Results Plexium Announces Multiple Presentations at AACR 2025 with Selective Monovalent Degrader Programs Targeting SMARCA2, IKZF2 and CDK2 plexium.com ↗
PLX-61639, a selective, oral SMARCA2 degrader, demonstrated sustained PD response and single-agent efficacy in SMARCA4 mutant tumors; program is advancing through IND-enabling studies |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Plexium, Inc. | Plexium Announces Multiple Presentations at AACR 2025 with Selective Monovalent Degrader Programs Targeting SMARCA2, IKZF2 and CDK2 plexium.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLX-61639 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284186 ↗ |
| Route | Oral | “PLX-61639 administered orally” NCT07284186 ↗ |
| Target | SMARCA2 | “Orally available degrader of SMARCA2” NCT07284186 ↗ |